uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

QURE 11.05.2024

SERA-AI Powered Highlights
Drug:AMT-130 AMT-130
Drug:AMT-162 AMT-162
Drug:AMT-191 AMT-191
Drug:AMT-260 AMT-260
Diseases:Huntington's disease
Diseases:SOD1-ALS
Diseases:Fabry disease
Diseases:mTLE
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:Guggenheim Healthcare Talks – Global Healthcare Conference
Date of Upcoming Event:2024-11-18
Name of Upcoming Event:Stifel 2024 Healthcare Conference
Full Press ReleaseSEC FilingsOur QURE Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - uniQure Announces Pricing of its Public Offering
  • 01.07.2025 - uniQure Announces Proposed Public Offering
  • 12.10.2024 - uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

Recent Filings

  • 01.08.2025 - 424B5 Prospectus [Rule 424(b)(5)]
  • 01.08.2025 - 8-K Current report
  • 01.08.2025 - EX-99.1 EX-99.1

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~

~ Presented positive interim data from Phase I/II trial of AMT-130 demonstrating slowing of Huntington’s disease progression and reductions in key biomarker of neurodegeneration ~

~ Initiated patient dosing in new Phase I/II studies of AMT-162 in SOD1-ALS and AMT-191 in Fabry disease; First patient enrolled in observational stage of Phase I/II study of AMT-260 in mTLE ~

~ Completed sale ofLexingtonmanufacturing facility and announced organizational restructuring expected to significantly reduce operating expenses and annual cash burn ~

~ Strong cash position of approximately$435 millionas ofSeptember 30, 2024, following retirement of$50 millionof debt, with cash runway through the end of 2027 ~

LEXINGTON, Mass.andAMSTERDAM,Nov. 05, 2024(GLOBE NEWSWIRE) --uniQureN.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the third quarter of 2024 and highlighted recent progress across its business.

“uniQure has made significant strides during the third quarter both clinically and operationally. We advanced our pipeline of clinical gene therapy programs, including the presentation of positive long-term follow-up data on AMT-130 supporting significant, dose-dependent slowing of Huntington’s disease progression,” statedMatt Kapusta, chief executive officer of uniQure. “We have scheduled a Type B meeting with the FDA for late November and welcome the opportunity, as part of the Regenerative Medicine Advanced Therapy (RMAT) designation, to discuss the potential for an accelerated development pathway for AMT-130. We believe the recently announced compelling clinical data, combined with AMT-130’s manageable safety profile and the lack of therapeutic options for patients in need, present a strong case for accelerated development. In addition, dosing has begun across two new Phase I/II studies in SOD1-ALS and Fabry disease, and we are making substantial progress towards the initiation of a third clinical trial in mesial temporal lobe epilepsy, with the first patient recently enrolling into the observational phase of the study.”

“We also delivered on one of our key corporate goals, which was to take meaningful actions to streamline operations and preserve capital. Following the sale of ourLexingtonmanufacturing facility, we announced a strategic reorganization expected to further reduce our cash burn and operating expenses,” he continued. “These decisions, which are delivering an immediate favorable impact, have extended our cash runway through the end of 2027 and multiple clinical and regulatory milestones with the potential to generate shareholder value.”

Mr. Kapustafurther commented, “Given the positive interim data on AMT-130, the upcoming Type B meeting, the sale of our manufacturing facility, commencement of three clinical trials and the rightsizing of our organization, uniQure has executed on its key short-term goals. Going forward we are turning our near-term focus toward working with the FDA in an effort to obtain an accelerated pathway for ATM-130 and further advancing our clinical pipeline. We look forward to providing updates on all our progress.”

Recent Company Updates

  • Advancing AMT-130 for the treatment of Huntington’s disease
    • Based on the granting of the RMAT designation, the Company has scheduled a Type B, multi-disciplinary meeting with theU.S. Food and Drug Administration(FDA) in late November at which the Company plans to present the most recent clinical data and initiate discussions regarding the potential for an expedited development pathway for AMT-130. The Company will also discuss with the FDA a future communication plan that is expected to include additional sub-disciplinary meetings to take place in the first half of 2025. Once the Company and the FDA define the registrational pathway for AMT-130, the Company expects to issue a public announcement.
    • InJuly 2024, uniQure announced positive interim data from the ongoingU.S.and European Phase I/II studies of AMT-130 for the treatment of early-stage Huntington’s disease1. At 24 months, the data demonstrated a statistically significant, dose-dependent slowing in disease progression measured by the composite Unified Huntington’s Disease Rating Scale (cUHDRS) in patients receiving the high dose of AMT-130 compared to a propensity score-weighted external control (p=0.007), as well as a statistically significant reduction of neurofilament light chain (NfL) in cerebrospinal fluid (CSF) in patients dosed with AMT-130 compared to baseline (p=0.02). AMT-130 continued to be generally well-tolerated with a manageable safety profile across both doses.
    • Patient dosing is ongoing in a third cohort of up to 12 patients to further evaluate both doses of AMT-130 together with an immunosuppression regimen, with a focus on evaluating near-term safety and tolerability. Enrollment in this third cohort is expected to be completed in the fourth quarter of 2024.
    • The Company expects to provide an additional interim update from its ongoing Phase I/II clinical trials of AMT-130 in mid-2025. The update will include follow-up data on all patients treated with AMT-130 in the first two cohorts, including three years of follow-up on 21 treated patients.
  • Initiating new Phase I/II clinical studies
    • AMT-191 for the treatment of Fabry disease– InAugust 2024, the Company announced that the first patient had been dosed in the Phase I/II clinical trial of AMT-191 for the treatment of Fabry disease. AMT-191 was granted Orphan Drug and Fast Track designations in September andOctober 2024, respectively. TheU.S., multi-center, open-label trial is expected to include up to 12 adult male patients across two dose cohorts.
    • AMT-162 for the treatment of SOD1 amyotrophic lateral sclerosis (ALS)– InOctober 2024, the Company announced that the first patient had been dosed in the Phase I/II clinical trial of AMT-162 for SOD1-ALS. TheU.S., multi-center, open-label trial is expected to include up to 12 patients across three dose cohorts.
    • AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (mTLE)– The first patient has been enrolled into the observational phase of the Phase I/II clinical trial of AMT-260 for the treatment of mTLE. The FDA-approved study protocol provides that the first three patients to be enrolled in the study are required to have MRI-confirmed unilateral, hippocampal sclerosis. Due to the more restrictive inclusion criteria for these sentinel patients, enrollment has taken longer than expected. The Company is rapidly activating recruitment sites with 10 centers currently open and an additional two sites expected to be activated by the end of 2024.
  • Capital preservation initiatives
    • InJuly 2024, the Company announced the closing of the sale of itsLexington, MAmanufacturing facility to Genezen.
    • InAugust 2024, the Company announced an organizational restructuring which, combined with theLexingtonmanufacturing facility sale, is expected to eliminate approximately 65% or 300 roles across the organization and reduce recurring cash burn by$70 millionper year.
    • In the third quarter of 2024, the Company made significant progress in reducing its operating expenses, with immediate benefit realized as a decrease in fixed costs from the sale of theLexingtonfacility and the reduction in personnel. The Company expects its expenses to further decline upon the completion of the restructuring, which is expected in the first half of 2025.
    • InJuly 2024, the Company retired$50 millionof its outstanding debt with Hercules Capital, which is expected to reduce annual interest expense by approximately$5 million. As ofSeptember 30, 2024, the Company had$50 millionof debt outstanding.

Upcoming Investor Events

  • Guggenheim Healthcare Talks – Global Healthcare Conference,November 12th–Boston, MA
  • Stifel 2024 Healthcare Conference,November 18th–New York, NY

Financial Highlights

Cash position:As ofSeptember 30, 2024, the Company held cash and cash equivalents and investment securities of$435.2 million, compared to$617.9 millionas ofDecember 31, 2023. The reduction in cash was in part driven by non-recurring payments made in the third quarter of 2024, including$53 millionrelated to the retirement of debt,$12Mof one-time payments related to theLexingtonfacility transaction, and$1Mof severance payments related to the Company’s corporate restructuring. Based on the Company’s current operating plan, the Company expects cash, cash equivalents and investment securities will be sufficient to fund operations through the end of 2027.

Revenues:Revenue for the three months endedSeptember 30, 2024was$2.3 million, compared to$1.4 millionin the same period in 2023. The increase of$0.8 millionin revenue resulted from a$1.6 millionincrease in license revenue, a decrease of$0.4 millionfrom collaboration revenue, and a decrease of$0.3 millionfrom contract manufacturing of HEMGENIX®forCSL Behring. Following the divestment of theLexingtonfacility inJuly 2024, revenue from contract manufacturing is recorded net of cost within other expenses.

Cost of contract manufacturing revenues:Cost of contract manufacturing revenues were$0.8 millionfor the three months endedSeptember 30, 2024, compared to$1.0 millionfor the same period in 2023. The decrease relates to the sale of theLexingtonfacility. Following the sale of theLexingtonfacility inJuly 2024, cost of contract manufacturing is recorded net of revenue within other expenses.

R&D expenses:Research and development expenses were$30.6 millionfor the three months endedSeptember 30, 2024, compared to$65.4 millionduring the same period in 2023. The$34.8 milliondecrease was related to a decrease of$14.6 millionrelated to changes in the fair value of contingent consideration, a$13.7 milliondecrease in employee-related expenses, partially offset by an increase of$3.4 millionseverance costs related to the reorganization announced inAugust 2024, a net decrease of$4.9 millionin external program spend and a$3.7 milliondecrease in costs incurred related to preclinical supplies.

SG&A expenses:Selling, general and administrative expenses were$11.6 millionfor the three months endedSeptember 30, 2024, compared to$18.1 millionduring the same period in 2023. The$6.5 milliondecrease was primarily related to a$4.0 milliondecrease in employee-related expenses, partially offset by an increase of$0.7 millionseverance costs related to the reorganization announced inAugust 2024, and a$1.3 milliondecrease in professional fees compared to the prior year period.

Other income:Other income was$2.6 millionfor the three months endedSeptember 30, 2024, compared to$1.4 millionduring the same period in 2023. The increase was primarily related to the$1.2 milliongain recorded on divesting theLexingtonmanufacturing facility.

Other expense: Other expense was$1.9 millionfor the three months endedSeptember 30, 2024, compared to$0.2 millionduring the same period in 2023. The increase was primarily related to$1.5 millionof non-cash expense recognized to amortize the right to purchase HEMGENIX®from Genezen on favorable terms.

Other non-operating items, net:Other non-operating items, net was an expense of$4.2 millionfor the three months endedSeptember 30, 2024, compared to$7.8 millionfor the same period in 2023. The$3.6 milliondecrease in other non-operating items, net was primarily related to an increase in net foreign currency gains of$7.4 million, which was partially offset by a decrease of$2.6 millionin interest income earned on investment securities and an increase in non-cash interest expense of$1.2 millionrelated to the royalty agreement that the Company entered into inMay 2023.

Net loss:The net loss for the three months endingSeptember 30, 2024, was$44.4 million, or$0.91basic and diluted loss per ordinary share, compared to$89.6 millionnet loss for the same period in 2023, or$1.88basic and diluted loss per ordinary share.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing apipelineof proprietary gene therapies for the treatment of patients withHuntington'sdisease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases.www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," “establish,” "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," “seek,” "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Examples of these forward-looking statements include, but are not limited to, statements concerning the Company’s cash runway and its ability to fund its operations through the end of 2027 and multiple milestones with the potential to generate shareholder value; the Company’s expectations regarding its organizational restructuring, including reductions in headcount and reductions in annual cash burn resulting the restructuring; the Company’s plans to announce additional interim updates from its ongoingU.S.and European Phase I/II clinical studies of AMT-130 in mid-2025 along with other future program updates; the Company’s plans to meet the FDA regarding potential expedited clinical development pathways for AMT-130; the strength of the Company’s case for accelerated development; the Company’s future communication plan and additional meetings with FDA expected to take place in the first half of 2025; the Company’s plans regarding the third cohort in its AMT-130 clinical trial and the timing of enrollment for such cohort; and the Company’s site activation plans for its AMT-260 clinical trial and the design of trials for its AMT-191, AMT-260 and AMT-162 programs. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks associated with the clinical results and the development and timing of the Company’s programs; the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to approval; the Company’s ability to continue to build and maintain the company infrastructure and personnel needed to achieve its goals; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the continued development and acceptance of gene therapies; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the Company’s ability to obtain, maintain and protect intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with theU.S. Securities & Exchange Commission(“SEC”), including its Annual Report on Form 10-K filedFebruary 28, 2024, its Quarterly Reports on Form 10-Q filedMay 7, 2024,August 1, 2024andNovember 5, 2024, and in other filings that the Company makes with theSECfrom time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

FOR INVESTORS:FOR MEDIA:
Chiara RussoTom Malone
Direct: 617-306-9137Direct: 339-970-7558
Mobile: 617-306-9137Mobile:339-223-8541
c.russo@uniQure.comt.malone@uniQure.com

uniQure N.V.
UNAUDITED CONSOLIDATED BALANCE SHEETS
September 30December 31,
20242023
(in thousands, except share and per share amounts)
Current assets
Cash and cash equivalents$251,626$241,360
Current investment securities183,615376,532
Inventories, net-12,024
Accounts receivable5,3224,193
Prepaid expenses19,28615,089
Other current assets and receivables4,2892,655
Total current assets464,138651,853
Non-current assets
Property, plant and equipment, net$25,566$46,548
Other investments28,260$2,179
Operating lease right-of-use assets14,83328,789
Intangible assets, net76,60960,481
Goodwill24,08426,379
Deferred tax assets, net10,86312,276
Other non-current assets1,4533,184
Total non-current assets181,668179,836
Total assets$645,806$831,689
Current liabilities
Accounts payable$5,441$6,586
Accrued expenses and other current liabilities32,30130,534
Current portion of contingent consideration29,23328,211
Current portion of operating lease liabilities4,2988,344
Total current liabilities71,27373,675
Non-current liabilities
Long-term debt51,113101,749
Liability from royalty financing agreement426,687394,241
Operating lease liabilities, net of current portion12,18528,316
Contingent consideration, net of current portion12,18114,795
Deferred tax liability, net7,6277,543
Other non-current liabilities8,9193,700
Total non-current liabilities518,712550,344
Total liabilities589,985624,019
Shareholders' equity
Total shareholders' equity55,821207,670
Total liabilities and shareholders' equity$645,806$831,689

uniQure N.V.
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
Three months endedSeptember 30,
20242023
(in thousands, except share and per share amounts)
Total revenues$2,287$1,407
Operating expenses:
Cost of license revenues(264)—
Cost of contract manufacturing revenues(757)(1,006)
Research and development expenses(30,595)(65,400)
Selling, general and administrative expenses(11,575)(18,074)
Total operating expenses(43,191)(84,480)
Other income2,5911,424
Other expense(1,915)(228)
Loss from operations(40,228)(81,877)
Non-operating items, net(4,181)(7,763)
Loss before income tax expense$(44,409)$(89,640)
Income tax benefit3169
Net loss$(44,378)$(89,571)
Basic and diluted net loss per ordinary share$(0.91)$(1.88)
Weighted average shares used in computing basic and diluted net loss per ordinary share48,718,53344,770,101

1All p-values are nominal and unadjusted. Statistical comparisons of patients treated with AMT-130 to the propensity score-weighted external control were conducted on a post-hoc basis.

This press release was published by a CLEAR® Verified individual.

Primary Logo

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com